S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
NASDAQ:CVAC

CureVac (CVAC) Stock Forecast, Price & News

$9.36
+0.25 (+2.74%)
(As of 06/2/2023 ET)
Compare
Today's Range
$9.14
$9.42
50-Day Range
$6.43
$10.46
52-Week Range
$5.63
$18.58
Volume
305,197 shs
Average Volume
651,199 shs
Market Capitalization
$2.10 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00

CureVac MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
124.4% Upside
$21.00 Price Target
Short Interest
Bearish
4.63% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.63
Upright™ Environmental Score
News Sentiment
0.17mentions of CureVac in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.04) to ($1.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

559th out of 983 stocks

Pharmaceutical Preparations Industry

276th out of 486 stocks


CVAC stock logo

About CureVac (NASDAQ:CVAC) Stock

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.

Receive CVAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CureVac and its competitors with MarketBeat's FREE daily newsletter.

CVAC Stock News Headlines

CureVac (NASDAQ:CVAC) Shares Up 3.7%
We Called (ARWR) In Advance, Which Stocks Are Next?
Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.
CureVac (CVAC) to Release Earnings on Tuesday
We Called (ARWR) In Advance, Which Stocks Are Next?
Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.
CureVac (CVAC) to Release Quarterly Earnings on Tuesday
CureVac (NASDAQ:CVAC) Price Target Cut to $24.00
CureVac (NASDAQ:CVAC) Trading 4.8% Higher
CureVac (NASDAQ:CVAC) Shares Down 2.2%
CureVac N.V.
CureVac N.V. (CVAC)
See More Headlines

CVAC Price History

CVAC Company Calendar

Last Earnings
11/29/2020
Today
6/03/2023
Next Earnings (Estimated)
7/25/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CVAC
Employees
1,049
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.00
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$18.00
Forecasted Upside/Downside
+124.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$72.33 million
Book Value
$3.42 per share

Miscellaneous

Free Float
219,029,000
Market Cap
$2.10 billion
Optionable
Not Optionable
Beta
2.87

Key Executives

  • Dr. Franz-Werner Haas L.L.M. (Age 53)
    LL.M., LLD, Ph.D., CEO, Member of Management Board & MD
    Comp: $575.16k
  • Mr. Pierre Kemula B.Sc. (Age 48)
    MD, CFO & Member of Management Board
    Comp: $606.97k
  • Dr. Ulrike Gnad-Vogt M.D. (Age 51)
    Ph.D., Interim Chief Devel. Officer, Sr. VP & Area Head of Oncology and Member of Exec. Board
    Comp: $232.53k
  • Dr. Igor Splawski M.Sc. (Age 54)
    Ph.D., Chief Scientific Officer & Member of Management Board
    Comp: $430.33k
  • Dr. Antony Blanc Ph.D. (Age 53)
    MD, Chief Bus. Officer, Chief Commercial Officer & Member of Management Board
    Comp: $370.81k
  • Mr. Malte Greune Ph.D. (Age 58)
    COO, Member of Management Board & MD
    Comp: $354.23k
  • Dr. Sarah Fakih
    VP Corp. Communications & Investor Relations
  • Mr. Marco Rau L.L.M.
    Ph.D., Gen. Counsel
  • Mr. Thorsten Schuller
    Head of Corp. Communications
  • Slavica Stevanovic-Heck
    Head of HR













CVAC Stock - Frequently Asked Questions

Should I buy or sell CureVac stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CureVac in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CVAC shares.
View CVAC analyst ratings
or view top-rated stocks.

What is CureVac's stock price forecast for 2023?

3 analysts have issued 12-month target prices for CureVac's shares. Their CVAC share price forecasts range from $18.00 to $24.00. On average, they expect the company's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 124.4% from the stock's current price.
View analysts price targets for CVAC
or view top-rated stocks among Wall Street analysts.

How have CVAC shares performed in 2023?

CureVac's stock was trading at $6.03 at the beginning of the year. Since then, CVAC stock has increased by 55.2% and is now trading at $9.36.
View the best growth stocks for 2023 here
.

Are investors shorting CureVac?

CureVac saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 4,310,000 shares, an increase of 19.4% from the April 30th total of 3,610,000 shares. Based on an average daily trading volume, of 561,300 shares, the short-interest ratio is currently 7.7 days. Approximately 4.6% of the shares of the company are short sold.
View CureVac's Short Interest
.

When is CureVac's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 25th 2023.
View our CVAC earnings forecast
.

How were CureVac's earnings last quarter?

CureVac (NASDAQ:CVAC) issued its quarterly earnings data on Sunday, November, 29th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($54.37) by $54.13.

What other stocks do shareholders of CureVac own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CureVac investors own include Moderna (MRNA), Tesla (TSLA), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Pfizer (PFE), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and NIO (NIO).

When did CureVac IPO?

(CVAC) raised $200 million in an IPO on Friday, August 14th 2020. The company issued 13,300,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse acted as the underwriters for the IPO and Berenberg and Kempen were co-managers.

What is CureVac's stock symbol?

CureVac trades on the NASDAQ under the ticker symbol "CVAC."

Who are CureVac's major shareholders?

CureVac's stock is owned by a variety of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (1.70%), BlackRock Inc. (0.88%), Balyasny Asset Management L.P. (0.50%), Alyeska Investment Group L.P. (0.47%), State Street Corp (0.12%) and Credit Suisse AG (0.11%).

How do I buy shares of CureVac?

Shares of CVAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CureVac's stock price today?

One share of CVAC stock can currently be purchased for approximately $9.36.

How much money does CureVac make?

CureVac (NASDAQ:CVAC) has a market capitalization of $2.10 billion and generates $72.33 million in revenue each year.

How many employees does CureVac have?

The company employs 1,049 workers across the globe.

How can I contact CureVac?

CureVac's mailing address is PAUL-EHRLICH-STRABE 15 TUBINGEN, BADEN-WURTTEMBERG 2M, 72076. The official website for the company is www.curevac.com. The company can be reached via phone at 49-70-71988-30, via email at investors@curevac.com, or via fax at 49-7071-9883.

This page (NASDAQ:CVAC) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -